Unternehmen Viracta Therapeutics, Inc. Nasdaq
Aktien
A2QEPW
US92765F1084
Biotechnologie
Kurzporträt
Mitarbeiterzahl: 40
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 62 | 19.09.22 |
Melody Burcar
DFI | Director of Finance/CFO | 41 | 01.09.22 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 07.08.23 |
Ayman El-Guindy
CTO | Chief Tech/Sci/R&D Officer | - | 06.07.21 |
Ivor Royston
BRD | Director/Board Member | 79 | 01.10.07 |
Ashleigh Barreto
IRC | Investor Relations Contact | - | 01.10.21 |
Corporate Officer/Principal | - | 06.07.21 | |
Patric Nelson
PRN | Corporate Officer/Principal | - | 06.07.21 |
Cheryl A. Madsen
LAW | General Counsel | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 01.10.07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 01.02.21 |
Barry Simon
BRD | Director/Board Member | 69 | 03.03.21 |
Mark Rothera
CEO | Chief Executive Officer | 62 | 19.09.22 |
Roger Pomerantz
CHM | Chairman | 67 | 01.06.20 |
Flavia Borellini
BRD | Director/Board Member | 65 | 14.08.21 |
Jane Barlow
BRD | Director/Board Member | 63 | 14.08.21 |
Stephen Rubino
BRD | Director/Board Member | 65 | 03.03.21 |
Sam Murphy
BRD | Director/Board Member | - | 01.01.19 |
Jane Chung
BRD | Director/Board Member | 53 | 10.08.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 39 272 434 | 38 184 370 ( 97,23 %) | 0 | 97,20 % |
Aktie B | 0 | 10 248 | 0 | 0 |
Unternehmenskontakt
Viracta Therapeutics, Inc.
2533 South Coast Highway 101 Suite 210
92007, Cardiff
+
http://www.viracta.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+25,69 % | 48,09 Mrd. | |
+46,90 % | 40,62 Mrd. | |
-3,46 % | 40,43 Mrd. | |
-6,20 % | 28,36 Mrd. | |
+9,17 % | 24,89 Mrd. | |
-20,42 % | 19,01 Mrd. | |
+28,07 % | 12,09 Mrd. | |
+0,17 % | 11,88 Mrd. | |
-1,24 % | 11,8 Mrd. |